Last reviewed · How we verify
Kremezin
At a glance
| Generic name | Kremezin |
|---|---|
| Also known as | AST-120, AST-120 (Kremezin) 2g three times a day |
| Sponsor | Tungs' Taichung Metroharbour Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) (PHASE3)
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) (PHASE3)
- AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease (PHASE4)
- AST-120 in Hemodialysis Patients With Uremic Pruritus (PHASE4)
- Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease (PHASE4)
- A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure (PHASE4)
- Pharmacokinetic Study of ASP1517 With Kremezin® (PHASE1)
- A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |